HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain. Building on the momentum from MWC 2025, the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order):MWC 2026 - Booth 6E44 at Hall 61 Entoptica Limited Devices & Systems2 eSIX Connectivity3 Faraconix Technologies Co., Ltd. Connectivity4 FreightAmigo Services Limited Digital Transformation5 Glassdio Scientific Company Limited Connectivity6 Harvest Elite International Limited Digital Transformation7 HongKong Umedia Limited Devices & Systems8 iASPEC Services Limited Digital Transformation9 InvestHK Ecosystem Partners10 Robocore Technology Limited Devices & Systems11 Shannon & Turing Technology Limited Connectivity12 The Hong Kong Polytechnic University Ecosystem Partners13 Xeroptix Technology Devices & Systems4YFN 2026 - Booth 8.1B31 at Hall 8.114 AIGM Limited Digital Transformation15 BWSea Technology (HK) Co., Limited Digital Transformation16 Cresento Limited Devices & Systems17 GoGoChart Technology Limited Digital Transformation18 HairCoSys Limited Devices & Systems19 KNQ Technology Limited Digital Transformation20 Solos Technology Limited Devices & Systems21 Vista Innotech Limited Devices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel: +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
HBO(SeaPRwire) - Game of Thrones 从来不是一个依赖“最后一秒揭秘”的系列。悬念当然有，但当字幕滚动时，一切就尘埃落定了。然而，《七王国的骑士》并非典型的《Game of Thrones》衍生剧——它有笑话、低俗歌曲，还有令人意外的片尾彩蛋。虽然我们最后一次看到邓肯与伊戈的情节，与他们的第一部中篇小说《雇佣骑士》（The Hedge Knight）的结局一致（尽管有细微调整），但片尾彩蛋却为两人的新冒险勾勒出完全不同的叙事视角，并为正在制作中的第二季铺垫了完美的副线剧情。警告！以下内容包含《七王国的骑士》（A Knight of the Seven Kingdoms）第一季第六集《明日》（“The Morrow”）的剧透！《雇佣骑士》的结尾是邓肯向梅卡·坦格利安请求让伊戈担任自己的侍从。书中写道：“夏宫亲王梅卡·坦格利安盯着‘跳蚤窝的邓肯’看了许久，银白胡须下的下巴无声地动着。最终他转身离去，一句话也没说。”次日清晨，伊戈告诉邓肯，梅卡派他来当侍从，于是两人启程出发。邓肯与伊戈未经梅卡·坦格利安允许便出发了。| HBO剧集中的情节大致如此；但在片尾彩蛋里，我们看到梅卡骑在马上，正准备出发前往君临，发疯似地寻找他的儿子。这清楚地表明：伊戈是偷偷溜走的——他根本没得到父亲的许可。但为什么要在一部其他方面都极其忠实于原著的剧集中做出这样的改动？答案藏在第二部邓肯与伊戈的中篇小说《誓言骑士》（The Sworn Sword）里——它将成为第二季的灵感来源。这本书的核心剧情是：效忠于某位前领主的骑士邓肯，调查一场关于小溪的争端。故事大致就是这样。现在回顾第一季，故事最精彩的部分之一就是坦格利安家族的参与——从已故但未被遗忘的贝勒，到我们又爱又恨的埃里昂。如果第二季完全照搬原著，那么除了伊戈（他发誓要对自己的身份保密）之外，不会有其他坦格利安家族成员出现。通过在第二季延续坦格利安家族的剧情线，《七王国的骑士》可以涵盖瓦拉·坦格利安因“大春疫”（Great Spring Sickness）去世的情节。| HBO如果梅卡从未批准伊戈与邓肯同行，那么第二季就能加入一条副线：梅卡在处理宫廷事务的同时，试图追踪儿子的下落。值得注意的是，第二季的时间线设定在“大春疫”席卷维斯特洛之后——这场瘟疫夺走了君临十分之四居民的生命，其中包括王位继承人瓦拉·坦格利安。如果《权力的游戏》的衍生剧《龙之家族》（House of the Dragon）证明了什么，那就是观众永远看不够坦格利安家族的故事。如果《七王国的骑士》想保持第一季的热度，那么这是让那些“银发巨头”留在故事中的完美方式——即便此时邓肯正在调查邻里之间的争端。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。
分类: 头条新闻,日常新闻
SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。A Knight of the Seven Kingdoms 现已在 HBO Max 流媒体平台播出。
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: +852-5983-9260Phone: +86-1392-3804-279Intelligent Joy Limited Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
TOKYO, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Head office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) will provide and donate gold, silver, and bronze medals to the top three men and women finishers of the marathon and wheelchair marathon events at the Tokyo Marathon 2026. The Tokyo Marathon 2026 is organized by the Tokyo Marathon Foundation and will be held on March 1, 2026.Design Representing All the Participants in the Event with Woven LinesThe medals were designed based on the concept of the Tokyo Marathon: The Day We Unite. On the front of the medal, the logo type is placed horizontally above the event logo pattern, which represents “runners, supporters, and cheerers,” to express the image of the Tokyo Marathon, which is held based on the involvement of many people, including runners, as well as volunteer staff and cheerers.On the back of the medal, the name of the event, Tokyo Marathon 2026, is written in Braille, and the words “FINISHER” and the event date are engraved, along with TANAKA’s logo. The medal’s ribbon design continues the 2016 design and is based on the event logo, which resembles a tapestry of lines woven together to represent all the runners, volunteers, and spectators.Sustainability InitiativesThe Tokyo Marathon 2026 is advancing sustainability initiatives centered on “waste reduction,” “environmental conservation,” and “DEI (Diversity, Equity & Inclusion).” In support of this initiative, the medal ribbons are made using recycled polyester. In addition, for the gold medals, the gold plating solution used is from TANAKA’s “RE Series” regenerated precious metals made using only 100% recycled materials. Through these initiatives, TANAKA is helping to make the event more sustainable.About the Tokyo Marathon 2026The Tokyo Marathon 2026 is the 19th edition of one of the largest public participation marathons in Japan. As it will celebrate its 20th anniversary in 2027, the event has evolved further to help all the participants play active roles so that the metropolis of Tokyo unite as one, based on three pillars: “The safest and most secure race in the world,” “The most exciting race in the world,” and “The warmest and most friendly race in the world.” This year, the event has adopted “Run. Tokyo. Own.” as the keyword to express how, on the grand stage of Tokyo, each runner lives their own run and their own story—and how countless individuals coming together create “one Tokyo” for that day and that moment alone.TANAKA has produced the winner and finisher medals for every Tokyo Marathon since the first held in 2007, with this year marking the 19th year. The Tokyo Marathon joined the World Marathon Majors (currently the Abbott World Marathon Majors) in 2013, attracting global attention as one of the world’s seven premier marathons. Other than the Tokyo Marathon, TANAKA has also produced medals for the winners of the Tokyo Legacy Half Marathon, supported the promotion of para sports as an official partner of the Japanese Para Sports Association (JPSA), and produced and sold official commemorative medals for the 1964 Tokyo Olympic Games. As part of its contribution to the realization of an inclusive society and the creation of a healthier society, TANAKA will continue to support the promotion of sports going forward.Overview of the Tokyo Marathon 2026 MedalsWeight, size and materialGold Medal: approx. 100g 65mm in diameter and approx. 3mm: pure silver with gold platingSilver Medal: approx. 100g 65mm in diameter and approx. 3mm: pure silverBronze Medal: approx. 85g 65mm in diameter and approx. 3mm: pure copper platingRace Information of the Tokyo Marathon 2026OrganizerTokyo Marathon FoundationCo-organizersJAAF (Japan Association of Athletics Federations); Tokyo Metropolitan Government;The Yomiuri Shimbun; Nippon Television Network Corporation; Sankei Shimbun Co., Ltd.; The Tokyo Shimbun.Managing OrganizationTokyo Athletics AssociationOperation SupporterTokyo Sports Association for the Disabled; Kanto Para Athletics.Supporting OrganizationsJAPAN SPORTS AGENCY; Ministry of Land, Infrastructure, Transport and Tourism; Japan Tourism Agency; Metropolitan Tokyo Mayors' Council; Japan Sports Association; Japanese Olympic Committee; Japanese Para Sports Association;Japan Para Athletics; Nippon Keidanren (Japan Business Federation);KEIZAI DOYUKAI (Japan Association of Corporate Executives);The Tokyo Chamber of Commerce and Industry; Tokyo Medical Association;Tokyo Disaster Prevention & Emergency Medical Service Association;Tokyo Private Ambulance Call Center Registered Companies Liaison Council;TOKYO NURSING ASSOCIATION; Tokyo Convention & Visitors Bureau;Tokyo Federation of Neighborhood Associations;Tokyo Federation of Shopping Center Promotion Associations & Tokyo Federation of Shopping Centers; Tokyo Sports Association; Community Sport Leaders Tokyo; Metropolitan Expressway Co., Ltd; The Hochi Shimbun; Radio Nippon Co., Ltd.;Sankei Sports; Nippon Broadcasting System, Inc.; The Tokyo Chunichi Sports.Presenting PartnerTokyo Metro Co., Ltd.Official PartnersSTARTS CORPORATION INC.; Mastercard; OujiSeiyaku Co., Ltd.;ASICS Japan Corp.; Otsuka Pharmaceutical Co., Ltd.;KINTETSU INTERNATIONAL; SEIKO GROUP CORPORATION;The Dai-ichi Life Insurance Company, Limited; McDonald's Company (Japan), Ltd.; Mizuho Bank, Ltd.; Kokumin Kyosai co-op (National Federation of Workers and Consumers Kyosai Cooperatives); Hisamitsu Pharmaceutical Co., Inc.;Kao Corporation; Earth Corporation; Porsche Japan K.K.; realbuzz; VENEX Co., Ltd.; NIHON KOHDEN CORPORATION; KOYOU RENTIA Co., Ltd.; Fanplus, Inc.;Shimizu Octo, Inc.; SAGAWA EXPRESS CO., LTD.;TANAKA PRECIOUS METAL GROUP Co., Ltd.; Rokko Butter, Co., Ltd.;Hibino Corporation; Photocreate Co., Ltd; ASUENE Inc.;DateSunday, March 1, 2026*The race information is current as of the time this press release was published. For the latest information, please check the Tokyo Marathon official website.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA PRECIOUS METAL GROUP Co., Ltd.TANAKA Corporate Websitehttps://www.tanaka.co.jp/english/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.co.jp/support/req/other_contact_e/index.htmlPress Release: https://www.acnnewswire.com/docs/files/20260224_EN.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
